Danova L A, Trishkina E A, Gershanovich M L
Vopr Onkol. 1983;29(2):46-51.
A more than 50% regression of tumor was observed in 19% of 64 patients treated with carminomycin for advanced primary breast cancer, its recurrences and metastases. A clinically-significant effect of treatment was recorded in 42%, while tumor process was arrested for at least 3-4 months in 37% of cases. The index of more than 50% regression of tumor rose to 28% in a group of 27 patients, following repeated courses of the drug. Only a slight toxic side--effect was observed, repeated courses included. Moderate leukopenia and a slight cardiotoxic effect were registered in 17%; phlebitis--in 12%. Carminomycin treatment should be recommended for advanced primary breast cancer, its recurrences an metastases, when other chemotherapeutic means fail to stop tumor process.
在64例接受卡米诺霉素治疗晚期原发性乳腺癌及其复发和转移的患者中，19%观察到肿瘤消退超过50%。42%记录到有临床意义的治疗效果，而37%的病例肿瘤进程至少停滞3 - 4个月。在27例患者组中，经过该药物的重复疗程后，肿瘤消退超过50%的比例升至28%。仅观察到轻微的毒副作用，包括重复疗程。17%出现中度白细胞减少和轻微心脏毒性作用；12%出现静脉炎。当其他化疗手段无法阻止肿瘤进程时，对于晚期原发性乳腺癌及其复发和转移，应推荐使用卡米诺霉素治疗。
